Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Pilot Study: Safety and Feasibility of Using Sorafenib as Neoadjuvant Treatment Prior to Orthotopic Liver Transplantation (OLT) in Patients With Hepatocellular Carcinoma|
- Adverse events associated with technical aspects of the operation [ Time Frame: post-transplant ]To assess the safety and feasibility of treating HCC patients with sorafenib prior to OLT, as determined by the number of patients experiencing grade 4 hemorrhaging needing blood trnasfusion, thrombosis of vascular graft structures, stenosis of vascular anastomosis or biliary leaks or anastomotic biliary stenosis.
- Time to progression prior to OLT [ Time Frame: 10 - 12 months ]A measure of time after being put on transplant list until the disease is beyond Milan's criteria prior to OLT.
- Drop Out Rate [ Time Frame: 10-12 months ]This is the rate of subjects who were eligible for liver transplant but drop out secondary to disease progression while awaiting donor organ.
- Waiting Time [ Time Frame: 10-12 months ]This is number of months from the time patient get listed on the transplant list to the time patient under goes actual liver transplant.
|Study Start Date:||September 2010|
|Study Completion Date:||January 2012|
|Primary Completion Date:||May 2011 (Final data collection date for primary outcome measure)|
• To evaluate safety (including possible surgical complication) and feasibility of using sorafenib as neo-adjuvant (bridging therapy) prior to orthotopic liver transplant(OLT).
The primary goal of this pilot study is to assess the safety and feasibility of treating HCC patients with sorafenib prior to OLT, as determined by the number of patients experiencing grade 4 hemorrhaging or bleeding post-operatively.
To achieve these goals a 2-stage accrual design will be used with a maximum accrual goal of 10 patients. Initially 5 patients will be entered on-study. If more than one patient experiences grade 4 hemorrhaging/bleeding following OLT the trial will be closed and sorafenib will not be considered safe and/or feasible. If no patient experiences this event 5 additional patients will be enrolled. At the end of the study sorafenib will be considered safe and feasible in this setting if no patient experience grade 4 hemorrhaging/bleeding following transplant. With this design, and assuming at least 3 of the 5 patients in each cohort undergo OLT, the likelihood of stopping early is <.04 if the underlying risk hemorrhages/bleeding are low (<5% each) whereas there is a >.42 chance of early termination if the risks are substantial (e.g. >.20 likelihood of dose limiting toxicity and >.30 likelihood of >grade 4 hemorrhages/bleeding). Overall the likelihood of accepting or not accepting sorafenib as safe and feasible are >.84, and <.16, respectively under these conditions.
- Drop out rate
- Time to progression prior to orthotopic liver transplant (OLT)
- Waiting time.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01337492
|United States, Ohio|
|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center|
|Cleveland, Ohio, United States, 44195|
|Principal Investigator:||Robert Pelley, MD||CCF Taussig Cancer Solid Tumor Oncology|